Biocon, Bristol-Myers sign drug deal

Comments 0
Biocon, which has been looking to partner the drug for nearly two years, said it would receive a licence fee as well as milestone payments and royalties based on commercial sales of the drug outside India.  (Reuters) Biocon, which has been looking to partner the drug for nearly two years, said it would receive a licence fee as well as milestone payments and royalties based on commercial sales of the drug outside India. (Reuters)
SummaryThe pact gives Bristol-Myers option to get the global licence to oral insulin drug programme.

million people worldwide and it is estimated that direct and indirect costs of the disease to overall healthcare system amounts to over USD 650 billion worldwide, Biocon said.

Shares of Biocon were today trading at Rs 304.65 per scrip on BSE, down 0.70 per cent from its previous close.

Single Page Format
Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...